Byamukama Sicklecell Foundation is proud to announce that its Founder and Director, Mr. Byamukama Fred Allan, participated as a speaker and presenter at the prestigious “Advancement of Treatments for Rare Diseases” Conference, held on 16–17 June 2026 at the Cyprus Institute of Neurology & Genetics (CING) in Nicosia, Cyprus. The high-level conference was organized by the Cyprus Institute of Neurology & Genetics in collaboration with the Deputy Ministry of Research, Innovation and Digital Policy as part of efforts to advance research, innovation, and treatment options for rare diseases globally. (Cyber Rare Diseases)
The conference brought together leading scientists, researchers, policymakers, patient advocates, pharmaceutical industry representatives, and health organizations from across Europe and beyond to discuss innovative approaches to rare disease prevention, diagnosis, treatment, and patient care. The event also highlighted the European Union’s ambition of becoming a global leader in life sciences by 2030 through stronger research partnerships and accelerated development of innovative therapies for rare diseases. (Cyber Rare Diseases)
During his presentation, Mr. Byamukama Allan shared valuable insights on the realities of living with and managing Sickle Cell Disease in Uganda, one of the most common genetic disorders affecting thousands of families across the country. He highlighted the challenges faced by patients, including delayed diagnosis, limited access to specialized healthcare services, inadequate awareness, high treatment costs, and the scarcity of advanced treatment options in many communities.
Drawing from the Foundation’s work, he showcased the efforts of byamukama sicklecell foundation in raising awareness about sickle cell disease, supporting affected individuals and families, promoting early testing and diagnosis, advocating for improved healthcare services, and conducting community outreach programs aimed at reducing the burden of the disease.
A key highlight of Mr. Byamukama’s presentation was his contribution to discussions on Gene Therapy, where he shared experiences and perspectives on the potential of emerging therapies to transform the lives of people living with genetic disorders such as sickle cell disease. He emphasized the need to ensure that breakthroughs in rare disease treatment are accessible not only in developed countries but also in low-resource settings where the burden of disease remains high.
Mr. Byamukama further called upon the European Commission, research institutions, healthcare organizations, and development partners to strengthen collaboration with African organizations and patient advocacy groups. He advocated for increased investment in research, capacity building, technology transfer, and partnerships that can help expand access to innovative treatments and improve outcomes for patients living with rare diseases across Africa.
“While scientific advances are creating new hope for people living with rare diseases, many patients in Uganda and across Africa are still unable to access quality healthcare and life-changing treatments. Global partnerships are essential if we are to ensure that no patient is left behind,” he noted.
The participation of Byamukama Foundation at this important international conference reflects the Foundation’s growing commitment to amplifying the voices of sickle cell patients, promoting research and innovation, and building strategic partnerships that contribute to better healthcare outcomes for individuals living with rare diseases.
As the Foundation continues its mission, it remains dedicated to advocating for equitable access to healthcare, advancing awareness of sickle cell disease, and fostering collaborations that create lasting impact for patients and communities in Uganda and beyond.
